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Abstract
Background: Elevated total plasma homocysteine (tHcy) has been associated with cognitive impairment, vascular disease
and brain atrophy.
Methods: We investigated 150 volunteers to determine if the association between high tHcy and cerebral grey matter
volume and cognitive function is independent of cardiovascular disease.
Results: Participants with high tHcy ($15 mmol/L) showed a widespread relative loss of grey matter compared with people
with normal tHcy, although differences between the groups were minimal once the analyses were adjusted for age, gender,
diabetes, hypertension, smoking and prevalent cardiovascular disease. Individuals with high tHcy had worse cognitive
scores across a range of domains and less total grey matter volume, although these differences were not significant in the
adjusted models.
Conclusions: Our results suggest that the association between high tHcy and loss of cerebral grey matter volume and
decline in cognitive function is largely explained by increasing age and cardiovascular diseases and indicate that the
relationship is not causal.
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Introduction
Homocysteine is an amino acid derived from dietary-obtained
methionine through demethylation [1]. Elevated total plasma
homocysteine (tHcy) has been implicated in a number of disease
processes including vascular diseases [2], dementia [3], cognitive
impairment [4], Raynaud’s phenomenon [5], osteoporotic frac-
tures [6], heart failure [7] and depression [8].
The observation that elevated tHcy is associated with vascular
disease dates back to the 1960s [9]. High tHcy increases the risk of
cerebrovascular disease, stroke and ischemic heart disease [10],
thromboembolic disease [11] and peripheral vascular disease [12].
It has also been associated with higher risk of congestive heart
failure independent of the presence of concurrent ischemic heart
disease [13]. In addition, a wealth of observational data indicates
an association between elevated tHcy and cognitive impairment
[14], although the few randomized controlled trials available to
date of homocysteine lowering treatment with B-vitamins have
generally failed to reduce the rate of cognitive decline in people at
risk [15].
Elevated tHcy has also been associated with anatomical and
neuroimaging changes of the brain. Data from the Sydney Stroke
Study showed that people with high tHcy have larger anterior
ventricle-brain ratio after controlling for age, folate, vitamin B12,
creatinine and white matter disease (OR=2.3, 95%CI 1.03–5.09)
[16]. High tHcy has also been associated with silent brain infarcts
and white matter lesions [17], and vascular disease is a well-
established risk factor for cognitive impairment and dementia [18].
There are numerous hypotheses as to how elevated tHcy
promotes brain atrophy and increases the risk of cognitive
impairment and dementia, independent of its role in the
pathogenesis of vascular disease [19]. However, the effect of
elevated tHcy on brain structure and function once prevalent
cardiovascular diseases are taken into account remains uncertain.
We designed this study to determine if high tHcy is associated
with lower cognitive function and with loss of cerebral grey matter
once the effect of prevalent cardiovascular disease and other
factors are taken into account. We specifically hypothesized that:
1) participants with elevated tHcy would show a greater degree of
grey matter loss compared to those with normal levels of tHcy, 2)
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participants with elevated tHcy would have worse performance on
tests of general intellectual functioning, memory and psychomotor
speed than people with normal tHcy, and that 3) these differences
would be independent of the presence of prevalent cardiovascular
disease and other vascular risk factors.
Methods
Study design
This is a cross-sectional analysis of participants aged 46–85
years who were recruited as part of the Heart-Mind study [20],
which was designed to determine the impact of cardiovascular
disease on cognition and brain structure over time. Data were
collected between May 2006 and March 2009 in Perth, Western
Australia.
Participants
This is a convenience sample of community-dwelling adults
recruited through advertisements in the local media or referrals
from general practitioners and hospital-based clinicians. Referring
hospitals included Royal Perth Hospital, Fremantle Hospital and
Sir Charles Gairdner Hospital. The Human Research Ethics
Committees of Royal Perth Hospital, Sir Charles Gairdner
Hospital and South Metropolitan Area Health Service approved
the study protocol and participants offered written informed
consent. The research was conducted in accordance with the
Declaration of Helsinki.
We excluded from participation people with: 1) prior clinical
history of stroke or cardiac arrest, 2) formal contraindication to
assessment with magnetic resonance imaging (MRI), 3) a score of
23 or less on the Mini-Mental State Examination (MMSE) [21], 4)
history of myocardial infarction within the preceding 30 days, 5)
clinically significant depressive or anxiety symptoms as determined
by Hospital Anxiety and Depression Scale (HADS) sub-scores of
greater than 10 [22], 6) visual or hearing impairment that was
sufficiently severe to interfere with the assessments, 7) difficulty
communicating in written and spoken English and 8) a serum
creatinine level .0.20 mmol/L.
Outcomes of interest
There were two main outcomes of interest: cerebral grey matter
volume and cognitive function. Brain images were acquired with a
1.5 Tesla SiemensH Symphony MRI scanner (TR: 2830 ms, TE:
4.48, flip angle: 15, matrix size: 25662566172, voxel size:
0.9 mm3). DICOM data were then converted to NIfTI file format
using MRIcron (http://www.mricron.com). We used Statistical
Parametric Mapping version 8 (SPM8 release 4010) software to
process the data on MatlabH 2010b (version 7.11.0.584). T1-
weighted images were skull-stripped, normalized and segmented
into grey matter (GM), white matter (WM) and cerebral spinal
fluid (CSF) with the VBM8 toolbox, version 359 (http://www.
dbm.neuro.uni-jena.de/vbm). We subsequently created GM and
WM templates using the SPM8 Dartel toolbox. Non-linear only
deformations were used to warp skull-stripped images to the
created templates using the VBM8 toolbox. The resultant
volumetric images (voxel size: 1.5 mm3) were smoothed with a
FWHM=10 mm Gaussian kernel. Images were acquired within
eight weeks of the clinical assessment (see below). Due to
acquisition artifact on a few images, parts of the left temporal
lobe were excluded from statistical analyses.
General cognitive functioning was assessed with the Cambridge
Cognitive Examination of the Elderly (CAMCOG) [23]. The
CAMCOG is a brief neuropsychological test that assesses a broad
range of cognitive functions including memory, attention,
concentration, calculation, executive functioning, language, praxis
and gnosis. The CAMCOG yields a total score of 105 with sub-
scores for the various cognitive domains. The CAMCOG is a well-
validated instrument with population-derived normative values
available [23]. Other cognitive outcomes of interest include the
immediate, short and delayed recall of the California Verbal
Learning Tests (CVLT) [24] and the Digit Copy and Coding
subtests of the Wechsler Adult Intelligence Scale [25]. The latter
two tests measure psychomotor planning and speed.
Main exposure
We collected fasting blood samples between 08:00 and 09:00 at
the Royal Perth Hospital Department of Biochemistry and these
were processed immediately to extract plasma and serum, which
were then batched and stored at 280uC until assayed. Total
plasma homocysteine concentration was determined by reverse
phase high performance liquid chromatography after treatment
with tributylphosphine, deproteinization and fluorogenic deriva-
tization using the method of Araki and Sako [26]. The coefficient
of variation ranged from 3% to 7%. High tHcy was defined as a
concentration of 15 mmol/L or greater [27].
Other variables of interest
Demographic, lifestyle and clinical data were obtained at the
initial assessment. Participants were asked about their age, marital
status, education (duration and highest level attained), exercise
pattern and smoking history. They were also asked about a history
of cardiovascular diseases, including symptoms of congestive heart
failure (CHF), angina and myocardial infarction, stroke, diabetes,
dyslipidemia and classified according to the New York Heart
Association (NYHA) rating scale. The MMSE was administered in
order to exclude people who showed evidence of cognitive
impairment.
Participants with cardiovascular diseases consisted of people
with stable CHF or with a positive history of ischemic heart disease
(IHD). People with CHF showed evidence of left ventricular
systolic dysfunction (ejection fraction – EF – less than 0.4) and had
a minimum six-month history of clinical symptoms consistent with
CHF [28]. We excluded participants with CHF class IV of the
NYHA Classification [29] due to significant morbidity and high
risk of mortality [30]. The diagnosis of ischemic heart disease was
based on clinical and biochemical evidence of past myocardial
infarction (i.e. raised creatinine kinase MB fraction, troponin I,
troponin T and ECG changes).
Alcohol use was quantified in terms of standard drinks
consumed per week and participants were classified into safe
and risky drinkers based on the current National Health and
Medical Research Council (NHMRC) of Australia’s safe drinking
guidelines of no more than two standard drinks a day (http://
www.nhmrc.gov.au/publications/synopses/ds10syn.htm). Partici-
pants who reported a total of 150 minutes or more of vigorous or
non-vigorous activity per week were considered physically active
[31]. We also measured participants, blood pressure weight and
height and calculated their body mass index (BMI, kg/m2).
All participants underwent an echocardiographic examination
to determine their left ventricular EF, which was calculated with
the following formula: final diastolic volume – final systolic
volume/final diastolic volume.
Statistical analysis
Data were analyzed with Stata version 11.2 (StataCorp, Texas).
Descriptive statistics were used to investigate the distribution of
data according to tHcy status. We used Student t tests to compare
differences between normal and high tHcy for normally
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distributed continuous variables and the Mann-Whitney test (z
statistic) for ordinal data. Skewed continuous variables were log-
transformed to assist in the analysis and values were reported as
geometric means. Chi-square or Fisher’s exact tests were used to
compare between-group distribution of proportions. The associ-
ation between cognitive outcomes and grey matter volume was
explored with a Pearson’s correlation (r statistic).
We used analysis of covariance (ANCOVA – F statistic) to
analyze the cognitive outcomes and overall grey matter volume
differences between participants with normal (tHcy,15 mmol/L)
and high tHcy (tHcy$15 mmol/L). We analyzed these outcomes
in three different ways: 1) unadjusted, 2) adjusted for age only, and
3) adjusted for the presence of diabetes, age, gender, hypertension,
smoking and prevalent cardiovascular disease. Participants’
cardiovascular disease status was categorized into 0 (no cardio-
vascular disease), 1 (IHD) and 2 (CHF) and this was entered as a
covariate in the adjusted model. These covariates comprised the
best-fit explanatory model of cognitive function and grey matter
volume according to tHcy status (all associated with a p value of
,0.05), and they all had a significant independent effect on tHcy
and cognitive function.
The selection of variables for the analysis of brain images
followed the same principles. We used a full 262 factorial SPM
design to model regional grey matter volume differences between
the groups. There was no need to covariate for total intracranial
volume during statistical analysis as nonlinear deformations were
used for normalization. We declared as significant a between group
difference of at least 100 voxels associated with a maximum p-value
of 0.01. The analysis was not corrected for multiple comparisons.
Results
Population characteristics
Table 1 summarizes the characteristics of the study population
according to tHcy status. Participants with elevated tHcy were on
average more than eight years older (t =25.01, p,0.001) and
were more likely to be male (x2 = 5.75, p = 0.016). These
individuals were also more likely to be current smokers (Fishers
exact test, p = 0.029), have CHF (x2 = 6.01, p= 0.014), diabetes
(x2 = 7.62, p = 0.006) and hypertension (x2 = 7.52, p= 0.006).
MRI findings
Participants with high tHcy (n= 49) showed evidence of
widespread loss of grey matter volume compared with people
with tHcy,15 mmol/L (n= 106) although differences between the
groups were much less pronounced once the analysis was adjusted
for age, gender, diabetes, hypertension, current smoking and
prevalent cardiovascular diseases. The relevant brain regions
included the left inferior occipital gyrus (Montreal Neurological
Institute coordinates [MNI] in mm -48, -80, 6, t = 5.56), left
parahippocampal gyrus (MNI -20, -35, -12, t = 5.48) and left
middle frontal gyrus (MNI -47, 30, 11, t = 5.39) (cluster
size = 138054) in the unadjusted analysis (Panel A, Figure 1).
There were also significant differences in the left superior frontal
gyrus (cluster size = 192, MNI -21, 18, 53, t = 2.83) and right
superior (MNI 12, 45, 44, t = 2.61) and medial frontal gyrus (MNI
15, 34, 44, t = 2.49) (cluster size = 123).
The differences were much less pronounced in the multivariate
model (Panel B, Figure 1). Participants with high tHcy had lower
grey matter volume in the left culmen of the cerebellum (MNI -14, -
33, -15, t = 3.83; -9, -54, 0, t = 3.46; -14, -30, -22, t = 3.26) (cluster
size= 2898), the right cerebellar tonsil (MNI 33, -54, -45, t = 3.06;
32, -45, -42, t = 2.82) (cluster size= 876), the left occipital lingual
gyrus (MNI -5, -89, 8, t = 2.88) (cluster size= 301), the middle gyrus
(MNI 34, -78, 17, t = 2.79) and cuneus of the right occipital lobe
(MNI 27, -77, 14, t = 2.72) (cluster size= 216), the right medial
frontal gyrus (cluster size= 175, MNI 18, 39, -15, t = 3.09) and the
right lentiform nucleus (cluster size= 162, MNI 23, -5, -13, t = 2.71).
Cognitive outcomes
We examined cognitive scores and total grey matter volume of
participants with high tHcy compared with normal tHcy. Total grey
matter volume was derived from the SPM analyses. Once again, we
adjusted the analyses for age, diabetes, hypertension, current
smoking, prevalent cardiovascular disease and gender. Table 2
summarizes the results of these analyses showing that participants
with high tHcy had worse cognitive function and significantly lower
grey matter volume than those with normal tHcy, although these
differences were no longer significant in the fully adjusted models.
Cognitive tests included measures of general cognitive function,
immediate recall, delayed recall and psychomotor planning and
speed. The adjusted CAMCOG score of participants with high
compared with normal tHcy was 0.8 points lower (95%CI 22.9 to
1.3, p= 0.476), but this difference was not statistically significant.
It is possible that the regional grey matter loss observed in
individuals with high tHcy may, at least in part, explain the poorer
cognitive function in these individuals. In our study however,
regional brain changes in grey matter (data not shown) were
essentially unchanged once cognitive scores were included in the
model. Total grey matter volume showed poor association with
cognitive function (Pearson correlation coefficient r = 0.18).
Subgroup analysis
Cardiovascular disease and elevated tHcy have been indepen-
dently associated with cognitive impairment and brain atrophy,
and with each other. Consequently, it is possible that our inclusion
of participants with prevalent cardiovascular disease may have
biased our findings towards a positive association. Hence, we
performed a subgroup analysis limited to participants who showed
no clinical or laboratory evidence of CHF or IHD (n= 64). Fifteen
of those had high tHcy. The latter showed evidence of widespread
grey matter volume loss compared to those with normal tHcy
(n= 49) although these differences were markedly attenuated once
the analyses were adjusted for age, gender, hypertension, current
smoking and diabetes. The significant brain areas in the adjusted
model were the left (MNI-9, -98, 2, t = 2.95) and right (MNI 9, -81,
-3, t = 3.36) lingual gyri and left cuneus (MNI -6, -87, 9, t = 2.76)
(cluster size = 829), the right cerebellar tonsil (cluster size = 811,
MNI 33, -59, -49, t = 3.46), the culmen of the left cerebellum
(cluster size = 589, MNI -9, -54, 0, t = 3.17; -5, -56, -18, t = 2.98),
the declive of the left cerebellum (cluster size = 124, MNI -12, -80,
-15, t = 2.94) and the left cerebral postcentral gyrus (cluster
size = 119, MNI -54, -17, 33, t = 2.71).
Individuals with elevated tHcy performed worse on all cognitive
measures but these differences were no longer apparent after
adjustment for age, diabetes, hypertension, smoking and gender.
The mean CAMCOG score in those with elevated tHcy was 90.7
(SD 1.1) compared to 95.7 (SD 1.1) with an adjusted p value of
0.276. Grey matter volume was lower in people with high tHcy
but this difference was not statistically significant (532.8 versus
554.7, adjusted p= 0.187).
Discussion
Main findings
The results of this cross-sectional study show that adults with
high tHcy have lower grey matter volume in a wide range of brain
regions, although differences relative to people with normal tHcy
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are limited once prevalent cardiovascular diseases and other
relevant confounding factors are taken into account in the analysis.
Additionally, individuals with elevated tHcy perform worse on
tests of global cognitive function, memory and psychomotor speed,
but these differences are no longer apparent once possible
confounding is taken into account.
Limitations
This study has weaknesses and strengths that merit comment.
We recruited a well-characterized group of community-dwelling
participants with well-defined cardiovascular disease profile, which
allowed us to adjust our analyses for their effect. We acknowledge,
however, that the generalizability of our findings could be limited
due to recruitment of motivated and referred volunteers. This type
of recruitment bias would have led to a selection of healthier
participants and minimization of differences between the groups,
thereby decreasing the power of the study to declare as significant
differences between the groups. Hence, the external validity of our
findings is uncertain. The cross-sectional nature of our study
design limits our ability to infer a causal relationship between high
tHcy, cognitive function and regional brain changes, although the
rationale for this study is consistent with previously reported
findings, and the hypothesis linking high tHcy to neurodegener-
ation and cognitive decline is supported by strong biological
plausibility [32,33,34,35]. We also acknowledge that our partic-
ipants were relatively young and free of significant cognitive
impairment and this has limited our ability to investigate the effect
of tHcy across the entire range of cognitive function and age.
We relied on a single estimation of tHcy and the duration of
exposure or variations in the concentration of tHcy over time
could not be taken into account in the analyses. Current evidence
suggests that a single measurement may underestimate the risk of
the outcome of interest because of regression dilution bias [36].
We used the cut-point of 15 mmol/L to define high tHcy, and
although this may be seen as a relative arbitrary definition, it does
take into account the results of numerous studies showing that
people with tHcy above these levels experience adverse health
events more frequently than their counterparts. Unmeasured
factors, such as participants’ vitamin B12 and folate concentration
and supplementation, renal function and apolipoprotein E
genotype status may have also contributed to confound the
observed associations. However, as our results show that the
adjusted differences in cognitive performance and grey matter
volume between participants with high versus normal tHcy are
minimal and of questionable clinical significance, it seems
improbable that these unmeasured factors would have enhanced
the differences between the groups. In fact, the opposite is more
likely to be true.
We used standardized procedures and statistical software to
analyze the imaging data. Voxel based morphometry is an
approach susceptible to type I error when used in exploratory
studies such as ours. We attempted to minimize this risk by
accepting as significant only brain regions where between group
differences were greater than 100 voxels and were associated with
alpha of 1% or less. Automated brain volume measurements are
generally accurate although measurement error of up to 5% may
Table 1. Participant characteristics according to tHcy status.
tHcy,15 mmol/L N=106 tHcy$15 mmol/L N=49 Statistic P value
Demographics
Age, mean (SD) 65.5 (10.1) 73.7 (7.9) t =25.01 ,0.001
Male gender, n (%) 54 (50.9) 35 (71.4) x2 = 5.75 0.016
Years of education, mean (SD) 12.5 (3.1) 11.9 (3.6) t = 1.09 0.276
Married, n (%) 79 (74.5) 37 (75.5) x2 = 0.00 0.971
Lifestyle
Ever smoked, n (%) 55 (51.9) 33 (67.3) x2 = 3.26 0.071
Current smoker, n (%) 3 (2.8) 6 (12.2) FET 0.029
Physically active, n (%) 29 (27.4) 10 (20.4) x2 = 0.86 0.354
BMI, mean (SD) 26.5 (4.3) 26.8 (3.6) t =20.39 0.700
Risky alcohol use, n (%) 36 (34.0) 12 (24.5) x2 = 1.41 0.236
Clinical
IHD, n (%) 39 (36.8) 17 (34.7) x2 = 0.06 0.800
CHF, n (%) 18 (17.0) 17 (34.7) x2 = 6.01 0.014
Diabetes, n (%) 13 (12.3) 15 (30.6) x2 = 7.62 0.006
Hypertension, n (%) 42 (39.6) 31 (63.3) x2 = 7.52 0.006
Dyslipidemia, n (%) 58 (54.7) 28 (57.1) x2 = 0.08 0.778
Systolic BP, mean (SD) 135.2 (19.5) 136.2 (23.6) t =20.27 0.787
Diastolic BP, mean (SD) 81.8 (11.4) 79.3 (12.6) t = 1.19 0.236
Ejection fraction, mean (SD) 61.7 (15.5) 56.0 (19.1) t = 1.98 0.049
HADSA, mean (SD)* 3.4 (2.1) 1.9 (2.0) z = 3.85 ,0.001
HADSD, mean (SD)* 2.2 (1.9) 2.2 (1.8) z =20.18 0.859
*Geometric mean.
Abbreviations: tHcy – total plasma homocysteine, FET – Fisher’s exact test, BMI – body mass index, IHD – ischemic heart disease, CHF – congestive heart failure, BP –
blood pressure, HADSA – hospital anxiety and depression scale anxiety score, HADSD - hospital anxiety and depression scale depression score.
doi:10.1371/journal.pone.0033345.t001
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occur [37]. This could be related to voxel misclassification, unclear
tissue edges and head tilt [38]. For this reason, we excluded from
the analysis a portion of the left temporal lobe where, we
suspected, tissue misclassification could have occurred. In
addition, we adjusted these analyses for a number of factors that
commonly affect grey matter volume, although we did not have
access to information about duration of prevalent cardiovascular
diseases and their treatment.
Our analyses included 91 participants who had common and
well-defined cardiovascular diseases (CHF and IHD). It is
conceivable that high tHcy leads to loss of cerebral grey matter
and a decline in cognitive function by increasing cerebrovascular
pathology, which would suggest that adjustment for prevalent
cardiovascular morbidity would represent an over-adjustment of
the analyses. We attempted to address this possibility by
completing a series of posthoc analyses that showed that the
pattern of structural and functional brain changes remained stable,
although we acknowledge that this subgroup analysis was
associated with loss of statistical power.
Finally, cognitive function was assessed with well-validated
standardized tools, but due to the cross-sectional design we are
unable to estimate the effect of tHcy on changes in cognitive
Figure 1. Grey matter density according to homocysteine status. This figure illustrates the regions in which participants with tHcy,15 mmol/
L had higher volume of grey matter compared to participants with elevated tHcy. Panel A shows the crude analysis and panel B shows the analysis
following adjustments for age, gender, diabetes, hypertension, current smoking and prevalent cardiovascular disease. The color illustrates the
magnitude of the differences with white (upper portion of the color palette) being the greatest.
doi:10.1371/journal.pone.0033345.g001
Table 2. Cognitive outcomes and total grey matter volume according to tHcy status.
tHcy,15 mmol/L
N=106
tHcy$15 mmol/L
N=49 F statistic P value
Age adjusted
P value
Fully adjusted
P value*
CAMCOG, mean** (SD) 94.8 (1.1) 90.9 (1.1) 13.54 ,0.001 0.010 0.224
CVLT immediate recall, mean (SD) 46.5 (10.8) 41.9 (11.5) 5.78 0.017 0.412 0.920
CVLT short delay recall, mean (SD) 9.5 (3.1) 7.9 (3.6) 8.08 0.005 0.352 0.997
CVLT long delay recall, mean (SD) 9.9 (3.4) 8.3 (3.4) 7.97 0.005 0.298 0.777
CVLT long delay cued recall, mean (SD) 10.5 (3.1) 9.1 (3.4) 7.00 0.009 0.331 0.791
Digit code, mean (SD) 57.8 (14.7) 44.9 (13.5) 26.46 ,0.001 0.020 0.194
Digit copy, mean (SD) 94.1 (23.4) 79.7 (20.8) 13.39 ,0.001 0.048 0.189
Grey matter volume, mean (SD) 561.6 (52.9) 538.0 (45.3) 7.33 0.008 0.164 0.208
*Adjusted for age, diabetes, gender, hypertension, current smoking and prevalent cardiovascular disease.
**Geometric mean.
Abbreviations: tHcy – total plasma homocysteine, CAMCOG – Cambridge cognitive examination of the elderly, CVLT – California verbal learning test.
doi:10.1371/journal.pone.0033345.t002
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function over time. Also, due to the exclusion of cognitively
impaired individuals, we are unable to comment on the potential
impact of tHcy on those with existing cognitive impairment or
dementia.
Interpretation of the findings
We found an inverse association between tHcy and grey matter
volume in our sample but this all but disappeared once prevalent
cardiovascular disease and risk factors were taken into account.
This suggests that the observed effect of tHcy on brain structure is
most likely mediated by age, gender and cardiovascular factors.
We concede that we might have over-adjusted the analyses given
the possibility that vascular factors may lie on the causal pathway
between tHcy and brain structure and function, but note that tHcy
is not the most important risk factor for cardiovascular disease
(http://www.heartfoundation.org.au). Hence, reducing the prev-
alence of other risk factors for cardiovascular disease may be more
important for brain structure and function than reducing tHcy.
Firbank and colleagues [39] studied 80 hypertensive subjects aged
70–90 years over a two-year period. They found that tHcy levels
correlated with hippocampal (p = 0.004) and white (p = 0.006), but
not grey (p = 0.6) matter atrophy rates. These findings are in
contrast, however, with data from the Rotterdam Scan study [40],
which showed that older adults had on average 0.23 units of
cortical atrophy (95%CI 0.07 to 0.38) per standard deviation
increase in tHcy. Their analyses were adjusted for relevant
vascular risk factors, although could not account for the presence
of cardiovascular disease as in our sample.
We found a small but statistically non-significant association
between high tHcy and poorer cognitive function. The differences
in cognitive function between the groups could not be explained
by regional grey matter differences despite the weak correlation
between grey matter volume and cognition as measured by the
CAMCOG. These findings are in contrast to data from the
VITACOG trial [41,42]. In that randomized trial, B-vitamins
reduced brain atrophy (0.76% per year for B vitamin group versus
1.08% for controls, p = 0.001), which in turn was associated with
cognitive changes over time (r =20.36, p,0.001). Participants in
this trial however were older than in our study ($70 years) and
had established cognitive impairment.
Taken together, our results suggest that the effects of high tHcy
on brain structure and function seem mostly due to the presence of
cardiovascular disease and increasing age. If that is the case,
lowering tHcy with B-vitamins will have limited effect on
neurocognitive outcomes if the concomitant impact of cardiovas-
cular diseases is not mitigated at the same time. Indeed, efforts to
improve cognitive function by lowering tHcy through B-vitamin
supplementation have been mostly unsuccessful to date [15].
Additionally, homocysteine lowering trials for the secondary
prevention of cardiovascular disease have also returned negative
results [43]. This is consistent with the view that preserving
cognitive function in later life is dependent on a number of factors
and that the chances of success will be greater if we focus on risk
reduction across a number of areas including lifestyle factors,
disease states and vascular risk. Recent reports suggest that a 10–
25% reduction in diabetes, midlife hypertension, midlife obesity
and smoking together with depression, low educational attainment
and cognitive inactivity could potentially prevent 1.1–3.0 million
cases of Alzheimer’s dementia worldwide [44,45].
Conclusion
Our results indicate that the association between high tHcy and
cognitive function and brain structure is largely driven by its
association with increasing age and cardiovascular diseases. These
findings suggest that interventions focused on the reduction of
tHcy alone will have limited impact on neurocognitive outcomes if
they fail to reduce the prevalence of cardiovascular diseases. We
suggest that effective preventive measures will need to take into
account, at the same time, the numerous risk factors for cognitive
decline in later life.
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